BioCentury | Feb 25, 2021
Management Tracks

Promotions at Anokion and GlycoMimetics; Read to chair TriNetX and moves at Lava, PYC, Quotient, ImmunoSCAPE and Emergex

...Ltd. as CBO. He was SVP, strategy and corporate development at Aduro Biotech Inc., with which Chinook Therapeutics Inc....
BioCentury | Jan 20, 2021
Product Development

Trucode reboots as Vera with Abingworth-led $80M series C, disease-modifying therapy for orphan kidney disease

...database, three other companies are targeting TNFSF13 or TNFSF13B to treat IgA nephropathy. Anti-APRIL (BION-1301) from Chinook Therapeutics Inc....
BioCentury | Nov 19, 2020
Finance

Syncona enters kidney disease space with gene therapy newco Purespring

...approach to kidney diseases is also gaining momentum. Companies such as Goldfinch Biopharma Inc. and Chinook Therapeutics Inc....
BioCentury | Oct 6, 2020
Deals

Oct. 5 Quick Takes: BridgeBio reacquiring Eidos, Amgen KRAS data, after-hours tumbles for Iovance, Y-mAbs and more

...Co. Ltd. Dynamk Capital Lucid Scientific Inc. Iovance Biotherapeutics Inc. Aduro Biotech Inc. Amgen Inc. BridgeBio Pharma Inc. Eidos Therapeutics Inc. Y-mAbs Therapeutics Inc. Chinook Therapeutics Inc....
BioCentury | Aug 19, 2020
Finance

Aug. 18 Quick Takes: Chinook fuels up for NASDAQ liftoff; plus Kymera, Poseida, Albireo

...Staff P-PSMA-101 Goofice (Brand), AJG533 (Compound #), A3309 (Compound #), elobixibat (Generic) Poseida Therapeutics Inc. Albireo Pharma Inc. Kymera Therapeutics Inc. Chinook Therapeutics Inc. Cancer Hepatic Prostate...
BioCentury | Jun 2, 2020
Deals

Personalized kidney play Chinook rounds out pipeline, lands on NASDAQ via Aduro deal

...Launched in 2019 with $65 million from Versant Ventures, Apple Tree Partners and Samsara Capital, Chinook Therapeutics Inc....
...protein alpha STING (TMEM173) - Transmembrane protein 173 Paul Bonanos, Associate Editor Xinlay, atrasentan (ABT-627) APRIL (BION-1301) Aduro Biotech Inc. Chinook Therapeutics Inc. CHK-336...
BioCentury | Jan 11, 2020
Company News

Chinook to spin AbbVie castoff into personalized kidney disease candidate

...receptor while transitioning it from the large diabetic nephropathy indication to a rare disease setting. Chinook Therapeutics Inc....
...molecule in other kidney diseases, possibly through a Phase II basket trial. Lauren Martz, Senior Editor AbbVie Inc. Chinook Therapeutics Inc. Versant...
BioCentury | Dec 5, 2019
Finance

With $75M from Apple Tree, Limelight seeks to overcome limitations of genetic therapy

...company Akero Therapeutics Inc. (NASDAQ:AKRO), genetic diseases play Stoke Therapeutics Inc. (NASDAQ:STOK) and kidney company Chinook Therapeutics Inc....
BioCentury | Oct 3, 2019
Product Development

Kidney is the new liver: why kidney indications are coming into sharp focus

...The most recent example was Versant Ventures’ August launch of precision medicine renal disease company Chinook Therapeutics Inc....
...potential cation channel subfamily C member 5 V2 receptor - Vasopressin 2 receptor Lauren Martz, Associate Editor Chinook Therapeutics Inc. Versant...
BioCentury | Aug 22, 2019
Financial News

Eyeing new endpoints, Versant-backed Chinook reels in $65M series A for kidney therapies

...$65 million in series A funding. Incubated within Versant Ventures' Inception Sciences drug discovery operation, Chinook Therapeutics Inc....
...Dobmeier and Davis. Dobmeier was COO of Seattle Genetics Inc. (NASDAQ:SGEN) until 2017. Paul Bonanos, Associate Editor Chinook Therapeutics Inc. renal...
Items per page:
1 - 10 of 11
BioCentury | Feb 25, 2021
Management Tracks

Promotions at Anokion and GlycoMimetics; Read to chair TriNetX and moves at Lava, PYC, Quotient, ImmunoSCAPE and Emergex

...Ltd. as CBO. He was SVP, strategy and corporate development at Aduro Biotech Inc., with which Chinook Therapeutics Inc....
BioCentury | Jan 20, 2021
Product Development

Trucode reboots as Vera with Abingworth-led $80M series C, disease-modifying therapy for orphan kidney disease

...database, three other companies are targeting TNFSF13 or TNFSF13B to treat IgA nephropathy. Anti-APRIL (BION-1301) from Chinook Therapeutics Inc....
BioCentury | Nov 19, 2020
Finance

Syncona enters kidney disease space with gene therapy newco Purespring

...approach to kidney diseases is also gaining momentum. Companies such as Goldfinch Biopharma Inc. and Chinook Therapeutics Inc....
BioCentury | Oct 6, 2020
Deals

Oct. 5 Quick Takes: BridgeBio reacquiring Eidos, Amgen KRAS data, after-hours tumbles for Iovance, Y-mAbs and more

...Co. Ltd. Dynamk Capital Lucid Scientific Inc. Iovance Biotherapeutics Inc. Aduro Biotech Inc. Amgen Inc. BridgeBio Pharma Inc. Eidos Therapeutics Inc. Y-mAbs Therapeutics Inc. Chinook Therapeutics Inc....
BioCentury | Aug 19, 2020
Finance

Aug. 18 Quick Takes: Chinook fuels up for NASDAQ liftoff; plus Kymera, Poseida, Albireo

...Staff P-PSMA-101 Goofice (Brand), AJG533 (Compound #), A3309 (Compound #), elobixibat (Generic) Poseida Therapeutics Inc. Albireo Pharma Inc. Kymera Therapeutics Inc. Chinook Therapeutics Inc. Cancer Hepatic Prostate...
BioCentury | Jun 2, 2020
Deals

Personalized kidney play Chinook rounds out pipeline, lands on NASDAQ via Aduro deal

...Launched in 2019 with $65 million from Versant Ventures, Apple Tree Partners and Samsara Capital, Chinook Therapeutics Inc....
...protein alpha STING (TMEM173) - Transmembrane protein 173 Paul Bonanos, Associate Editor Xinlay, atrasentan (ABT-627) APRIL (BION-1301) Aduro Biotech Inc. Chinook Therapeutics Inc. CHK-336...
BioCentury | Jan 11, 2020
Company News

Chinook to spin AbbVie castoff into personalized kidney disease candidate

...receptor while transitioning it from the large diabetic nephropathy indication to a rare disease setting. Chinook Therapeutics Inc....
...molecule in other kidney diseases, possibly through a Phase II basket trial. Lauren Martz, Senior Editor AbbVie Inc. Chinook Therapeutics Inc. Versant...
BioCentury | Dec 5, 2019
Finance

With $75M from Apple Tree, Limelight seeks to overcome limitations of genetic therapy

...company Akero Therapeutics Inc. (NASDAQ:AKRO), genetic diseases play Stoke Therapeutics Inc. (NASDAQ:STOK) and kidney company Chinook Therapeutics Inc....
BioCentury | Oct 3, 2019
Product Development

Kidney is the new liver: why kidney indications are coming into sharp focus

...The most recent example was Versant Ventures’ August launch of precision medicine renal disease company Chinook Therapeutics Inc....
...potential cation channel subfamily C member 5 V2 receptor - Vasopressin 2 receptor Lauren Martz, Associate Editor Chinook Therapeutics Inc. Versant...
BioCentury | Aug 22, 2019
Financial News

Eyeing new endpoints, Versant-backed Chinook reels in $65M series A for kidney therapies

...$65 million in series A funding. Incubated within Versant Ventures' Inception Sciences drug discovery operation, Chinook Therapeutics Inc....
...Dobmeier and Davis. Dobmeier was COO of Seattle Genetics Inc. (NASDAQ:SGEN) until 2017. Paul Bonanos, Associate Editor Chinook Therapeutics Inc. renal...
Items per page:
1 - 10 of 11